cafdad227b8.Ckboku4KOW9gLwi_TYBiuZj5_rZRyAyaLl8DzaeR7Wg.fjy5_ao7fVYoeDngObVT88GhsttnqWjCYj5c9f3H3Cd8FYDDpVlYXDNwRQ
11-10 Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 CI
11-10 Protalix BioTherapeutics, Inc., Q3 2026 Earnings Call, Nov 10, 2026
11-10 Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-10 Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results PR
11-09 Protalix BioTherapeutics Presents Data Supporting Potential For Less Frequent Dosing Of PRX-115 In Phase 2 RELEASE Study For Uncontrolled Gout CI
11-09 Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations PR
11-03 Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026 PR
10-26 Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference PR
09-16 Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
09-08 Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences PR
08-12 Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12 Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Protalix: Q2 Earnings Snapshot AQ
08-12 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results PR
08-12 Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026 CI
08-05 Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 PR
05-13 Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
05-13 Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-13 Protalix BioTherapeutics : PLX Corporate Presentation (May 2026) PU
05-13 Protalix: Q1 Earnings Snapshot AQ
05-13 Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results PR
05-13 Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026 CI
05-06 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 PR
03-18 Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa CI
03-18 Top Midday Decliners MT

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. PLX Stock
  4. News Protalix BioTherapeutics, Inc.